Neuren Pharmaceuticals (ASX:NEU) was granted a type C Meeting with the US Food and Drug Administration to discuss the primary efficacy endpoints of its phase 3 clinical trial program for a neurodevelopmental disorder drug candidate, the company said in a Friday Australian bourse filing.
The drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders and achieved positive results in phase 2 clinical trials in Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.